［1］周良辅,毛颖,王任直.中国中枢神经系统胶质瘤诊断与治疗指南(2015)［J］.中华医学杂志,2016,96(07):485-509.
ZHOU LF,MAO Y,WANG RZ.Guidelines for diagnosis and treatment of glioma of the central nervous system in China(2015)［J］.National Medical Journal of China,2016,96(07):485-509.
［2］ ZHANG B,WU Q,LI B,et al.m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer［J］.Mol Cancer,2020,19(1):53.
［3］ HALL RH.A general procedure for the isolation of "Minor" nucleosides from ribonucleic acid hydrolysates［J］.Biochemistry,1965,4:661-670.
［4］ ZHANG Y,GENG X,LI Q,et al.m6A modification in RNA:biogenesis,functions and roles in gliomas［J］.J Exp Clin Cancer Res,2020,39(1):192.
［5］宋海飞,余诗俊,高勇.m6A甲基化在多种消化道肿瘤中的研究进展［J］.现代肿瘤医学,2020,28(20):3613-3616.
SONG HF,YU SJ,GAO Y.Role of m6A methylation in digestive system tumor［J］. Modern Oncology,2020,28(20):3613-3616.
［6］LIU ZX,LI LM,SUN HL,et al.Link between m6A modification and cancers［J］.Front Bioeng Biotechnol,2018,6:89.
［7］ HUANG H,WENG H,ZHOU K,et al.Histone H3 trimethylation at lysine 36 guides m6A RNA modification co-transcriptionally［J］.Nature,2019,567(7748):414-419.
［8］ MENDEL M,CHEN KM,HOMOLKA D,et al.Methylation of structured RNA by the m6A writer METTL16 is essential for mouse embryonic development［J］.Mol Cell,2018,71(6):986-1000.
［9］ PING XL,SUN BF,WANG L,et al.Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase［J］.Cell Res,2014,24(2):177-189.
［10］ KNUCKLES P,LENCE T,HAUSSMANN IU,et al.Zc3h13/Flacc is required for adenosine methylation by bridging the mRNA-binding factor Rbm15/Spenito to the m6A machinery component Wtap/Fl(2)d［J］.Genes Dev,2018,32(5-6):415-429.
［11］LI J,YANG X,QI Z,et al.The role of mRNA m6A methylation in the nervous system［J］.Cell Biosci,2019,9:66.
［12］ PENDLETON KE,CHEN B,LIU K,et al.The U6 snRNA m6A methyltransferase METTL16 regulates SAM Synthetase intron retention［J］.Cell,2017,169(5):824-835.
［13］潘红丽,李雪冰,陈琛,等.m6A RNA甲基化在非小细胞肺癌中的研究进展［J］.中国肺癌杂志,2020,23(11):961-969.
PAN HL,LI XB,CHEN C,et al.Research advances of m6A RNA methylation in non-small cell lung cancer［J］.Chinese Journal of Lung Cancer,2020,23(11):961-969.
［14］ GARCIA-CAMPOS MA,EDELHEIT S,TOTH U,et al.Deciphering the "m6A Code" via antibody-independent quantitative profiling［J］.Cell,2019,178(3):731-747.
［15］ ZHANG S,ZHAO BS,ZHOU A,et al.m6A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program［J］.Cancer Cell,2017,31(4):591-606.
［16］ DONG Z,CUI H.The emerging roles of RNA modifications in glioblastoma［J］.Cancers(Basel),2020,12(3):736.
［17］ WANG J,SHA Y,SUN T.m6A modifications play crucial roles in glial cell development and brain tumorigenesis［J］.Front Oncol,2021,11:611660.
［18］ SHI H,WANG X,LU Z,et al.YTHDF3 facilitates translation and decay of N6-methyladenosine-modified RNA［J］.Cell Res,2017,27(3):315-328.
［19］ LIU N,ZHOU KI,PARISIEN M,et al.N6-methyladenosine alters RNA structure to regulate binding of a low-complexity protein［J］.Nucleic Acids Res,2017,45(10):6051-6063.
［20］ MEYER KD,PATIL DP,ZHOU J,et al.5' UTR m6A promotes cap-independent translation［J］.Cell,2015,163(4):999-1010.
［21］ WU R,LI A,SUN B,et al.A novel m6A reader Prrc2a controls oligodendroglial specification and myelination［J］.Cell Res,2019,29(1):23-41.
［22］ YEN YP,CHEN JA.The m6A epitranscriptome on neural development and degeneration［J］.J Biomed Sci,2021,28(1):40.
［23］ CHOI J,IEONG KW,DEMIRCI H,et al.N6-methyladenosine in mRNA disrupts tRNA selection and translation-elongation dynamics［J］.Nat Struct Mol Biol,2016,23(2):110-115.
［24］ LI Y,XIAO J,BAI J,et al.Molecular characterization and clinical relevance of m6A regulators across 33 cancer types［J］.Mol Cancer,2019,18(1):137.
［25］ VU LP,PICKERING BF,CHENG Y,et al.The N6-methyladenosine(m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells［J］.Nat Med,2017,23(11):1369-1376.
［26］ LI Z,WENG H,SU R,et al.FTO plays an oncogenic role in acute myeloid leukemia as a N6-methyladenosine RNA demethylase［J］.Cancer Cell,2017,31(1):127-141.
［27］ WENG H,HUANG H,WU H,et al.METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m6A modification［J］.Cell Stem Cell,2018,22(2):191-205.
［28］ HAN SH,CHOE J.Diverse molecular functions of m6A mRNA modification in cancer［J］.Exp Mol Med,2020,52(5):738-749.
［29］ ZHANG C,ZHANG M,GE S,et al.Reduced m6A modification predicts malignant phenotypes and augmented Wnt/PI3K-Akt signaling in gastric cancer［J］.Cancer Med,2019,8(10):4766-4781.
［30］ BAI Y,YANG C,WU R,et al.YTHDF1 regulates tumorigenicity and cancer stem cell-like activity in human colorectal carcinoma［J］.Front Oncol,2019,9:332.
［31］ KLUGHAMMER J,KIESEL B,ROETZER T,et al.The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space［J］.Nat Med,2018,24(10):1611-1624.
［32］ JIA D,LIN W,TANG H,et al.Integrative analysis of DNA methylation and gene expression to identify key epigenetic genes in glioblastoma［J］.Aging(Albany NY),2019,11(15):5579-5592.
［33］ BRANDES AA,FRANCESCHI E,PACCAPELO A,et al.Role of MGMT methylation status at time of diagnosis and recurrence for patients with glioblastoma:clinical implications［J］.Oncologist,2017,22(4):432-437.
［34］ LI F,ZHANG C,ZHANG G.m6A RNA methylation controls proliferation of human glioma cells by influencing cell apoptosis［J］.Cytogenet Genome Res,2019,159(3):119-125.
［35］ KOWALSKI-CHAUVEL A,LACORE MG,ARNAUDUC F,et al.The m6A RNA demethylase ALKBH5 promotes radioresistance and invasion capability of glioma stem cells［J］.Cancers(Basel),2020,13(1):40.
［36］ GE L,ZHANG N,CHEN Z,et al.Level of N6-methyladenosine in peripheral blood RNA:A novel predictive biomarker for gastric cancer［J］.Clin Chem,2020,66(2):342-351.
［37］ KONNO M,KOSEKI J,ASAI A,et al.Distinct methylation levels of mature microRNAs in gastrointestinal cancers［J］.Nat Commun,2019,10(1):3888.
［38］ STRICK A,VON HAGEN F,GUNDERT L,et al.The N6 -methyladenosine(m6 A) erasers alkylation repair homologue 5(ALKBH5) and fat mass and obesity-associated protein(FTO) are prognostic biomarkers in patients with clear cell renal carcinoma［J］.BJU Int,2020,125(4):617-624.
［39］ XU C,YUAN B,HE T,et al.Prognostic values of YTHDF1 regulated negatively by mir-3436 in Glioma［J］.J Cell Mol Med,2020,24(13):7538-7549.
［40］ CHAI RC,WU F,WANG QX,et al.m6A RNA methylation regulators contribute to malignant progression and have clinical prognostic impact in gliomas［J］.Aging(Albany NY),2019,11(4):1204-1225.
［41］ CHENG Y,HE C,WANG M,et al.Targeting epigenetic regulators for cancer therapy:mechanisms and advances in clinical trials［J］.Signal Transduct Target Ther,2019,4:62.
［42］ SENFT D,QI J,RONAI ZA.Ubiquitin ligases in oncogenic transformation and cancer therapy［J］.Nat Rev Cancer,2018,18(2):69-88.
［43］ CULLY M.Chemical inhibitors make their RNA epigenetic mark［J］.Nat Rev Drug Discov,2019,18(12):892-894.
［44］ SELBERG S,BLOKHINA D,AATONEN M,et al.Discovery of small molecules that activate RNA methylation through cooperative binding to the METTL3-14-WTAP complex active site［J］.Cell Rep,2019,26(13):3762-3771.
［45］ IANNIELLO Z,PAIARDINI A,FATICA A.N6-methyladenosine(m6A):A promising new molecular target in acute myeloid leukemia［J］.Front Oncol,2019,9:251.
［46］ LE DT,KIM TW,VAN CE,et al.Phase II open-label study of pembrolizumab in treatment-refractory,microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer:KEYNOTE-164［J］.J Clin Oncol,2020,38(1):11-19.
［47］ LI Y,GU J,XU F,et al.Molecular characterization,biological function,tumor microenvironment association and clinical significance of m6A regulators in lung adenocarcinoma［J］.Brief Bioinform,2021,22(4):1-17.